NRx Pharmaceuticals, Inc. announced that the Class I directors are Chaim Hurvitz and Daniel Troy, and their terms will expire at 2022 annual meeting of stockholders. Daniel Troy will not be standing for reelection to the Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.06 USD | +45.71% | -13.80% | -33.48% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.48% | 21.88M | |
+22.81% | 47.9B | |
+46.56% | 41.42B | |
-1.88% | 40.7B | |
-6.20% | 28.92B | |
+11.33% | 25.55B | |
-21.00% | 19.27B | |
-1.43% | 12.15B | |
+30.73% | 12.14B | |
-0.48% | 11.99B |
- Stock Market
- Equities
- BRPA Stock
- News NRx Pharmaceuticals, Inc.
- Nrx Pharmaceuticals, Inc. Announces Director Resignation